✦ LIBER ✦

A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy

✍ Scribed by T Betts; T Waegemans; P Crawford

Book ID: 117832280
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 105 KB
Volume: 9
Category: Article
ISSN: 1059-1311
DOI: 10.1053/seiz.2000.0380

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy, safety, and effects on blood p

Efficacy, safety, and effects on blood pressure of naproxcinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip: A randomized, double-blind, parallel-group, multicenter study

✍ Christoph Baerwald; Paolo Verdecchia; Brigitte Duquesroix; Hayet Frayssinet; Thi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 372 KB 👁 3 views

Efficacy and Tolerability of Once-Daily

Efficacy and Tolerability of Once-Daily Oral Fimasartan 20 to 240 mg/d in Korean Patients with Hypertension: Findings from Two Phase II, Randomized, Double-Blind, Placebo-Controlled Studies

✍ Howard Lee; Han-Mo Yang; Hae-Young Lee; Jae-Joong Kim; Dong-Ju Choi; Ki-Bae Seun 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 843 KB

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre

80* A randomised, double-blind, placebo-

80* A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 μg and 5 μg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis

✍ J.S. Elborn; A. Sharma; Q. Deng; P. Koker 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 51 KB